Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 20, 2020British Journal of HaematologyOpen Access

Prognostic indices in diffuse large B‐cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R‐CHOP 14 versus 21 phase 3 trial

View Full Paper
Ask AI
Bookmark
Share

Authors

MGMary GleesonGuy's and St Thomas' NHS Foundation TrustNCNicholas CounsellCancer Research UK
David Cunningham
David CunninghamRutgers, The State University of New Jersey

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Gleeson et al. (2020) studied this question.

synapsesocial.com/papers/6aae563c50dfceb7fdf22952https://doi.org/10.1111/bjh.16691
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era2013 · 967 citations
  2. 2Validation of the NCCN ‐ IPI for diffuse large B‐cell lymphoma ( DLBCL ): the addition of β2‐microglobulin yields a more accurate GELTAMO ‐ IPI2017 · 82 citations
  3. 3Delineating outcomes of patients with diffuse large b cell lymphoma using the national comprehensive cancer network‐international prognostic index and positron emission tomography‐defined remission status; a population‐based analysis2015 · 32 citations
  4. 4Standard International Prognostic Index Remains a Valid Predictor of Outcome for Patients With Aggressive CD20<sup>+</sup>B-Cell Lymphoma in the Rituximab Era2010 · 592 citations
  5. 5A Predictive Model for Aggressive Non-Hodgkin's Lymphoma1993 · 5,009 citations